The lethal effects of endotoxin, a bacterial product shed into the blood during bacteremia, are thought to be due to macrophage release of mediators such as tumor necrosis factor a and interleukin 1. Although much is known about the pathophysiology of endotoxemia, relatively little is known about the cellular gnaling mechanisms that are involved. The data in this study suggest that extracellular adenine nucleotides can influence the development of endotoxin shock. An adenine nucleotide analog, 2-methylthio-ATP, inhibited the endotoxin-stimulated release of toxic mediators (i.e., tumor necrosis factor a and interleukin 1), and it protected mice from endotoxin-induced death. These studies suggest a fundamental and unusual role for adenine nucleotides on endotoxin action, and they provide a potentially new therapeutic approach for the control of the pathophysiology of Gram-negative septicemia.
Gram-negative septic shock is characterized by a high mortality rate, resulting in thousands ofdeaths annually. Much of the pathophysiology of Gram-negative sepsis can be reproduced by the action of bacterial endotoxin (Gram-negative bacterial lipopolysaccharide; LPS), which triggers a cascade of immunologic events (1) (2) (3) (4) (5) . In humans and some animal models, plasma concentrations of LPS less than 1 ng/ml can induce the release of mediators such as tumor necrosis factor a (TNF-a), interleukin 1 (IL-1), and interleukin 6 (IL-6), which play a central pathogenic role in this disease process (1) (2) (3) (4) (5) . Macrophages are particularly important cells in LPSmediated TNF-a, IL-1, and IL-6 release (2) . A detailed understanding of the cellular and biochemical processes through which LPS activates macrophages is unknown. However, several components appear to be utilized, including an interaction with CD14 (6), the involvement of GTPbinding proteins (G proteins) (7) (8) (9) (10) (11) , and the activation of kinase cascades (12, 13) . In general, an amplification system in the initial response is suggested because minute quantities of LPS are able to induce severe toxicity in several mammalian species, including humans.
Several lines of indirect evidence suggest that G proteins may be involved in LPS action (7) (8) (9) (10) (11) , which would be consistent with a receptor-linked cellular amplification pathway. Heterotrimeric and small molecular weight G proteins are known to be linked to various hormone receptors, and these G proteins are essential for multiple signal-transduction processes. Ligand activation of a G protein-coupled receptor promotes the exchange of GTP for GDP on the G protein.
Depending upon the class of G-protein, these GTP-G-protein complexes are then able to direct the activation of a number of enzymes-e.g., adenylate cyclase, raf-1, and phospholipases (14) . Down-regulation of the G protein involves hydrolysis of the GTP to GDP by an intrinsic GTPase activity. Hence, GTPase activity is a hallmark of G-protein activation and involvement in various signaling events (15) . Our recent report that LPS stimulates a RAW 264.7 macrophage membrane-associated GTPase activity (16) further supports a role for G proteins in endotoxicity.
During the course of studying this LPS action, we made the unexpected observation that ATP greatly enhanced the LPS stimulation of macrophage membrane GTPase activity (16) . Macrophages are likely to be exposed to extracellular ATP and ADP in vivo as these compounds are released from platelets and other cells during inflammation or injury (17) (18) (19) (20) . Several G protein-coupled purinoreceptors exist that use ATP/ADP as an agonist and are expressed in macrophages (17) (18) (19) . Therefore, we examined the possible linkage of macrophage purinoreceptors to the LPS-responsive GTPase activity. These studies identified a weak agonist-namely, 2-methylthio-ATP (2-MeS-ATP). Because tight receptor binding allows many weak agonists to act as effective antagonists of other more active agents, we assessed the ability of 2-MeS-ATP to prevent the interaction between LPS and ATP/ADP. We report that 2-MeS-ATP stimulates basal GTPase activity yet blocks the synergistic effect seen with ADP and LPS; hence, 2-MeS-ATP acts as a partial agonist as suggested by others (21 GTPase Assay. GTPase activity was assayed by using macrophage membranes as described (16 
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Proc. Natl. Acad. Sci. USA 91 (1994) Cytokine Assays. Male BALB/c mice (2-3 months old, 25-35 g) were ether-anesthetized and injected with 100 p1 of saline containing 0 or 800 pg of LPS (E. coli 0111:B4) and 0, 3.66, or 36.6 mg of 2-MeS-ATP per kg of weight. After LPS administration, the animals were euthanized by cervical dislocation at 0 and 1 hr for TNF-a determinations and at 0 and 4 hr for IL-la and IL-6 measurements. Blood was obtained by cardiac puncture, and serum from each animal was assayed individually. Serum cytokine levels were determined by using the methods for ELISA detailed by the manufacturers: TNF-a and IL-6 (Endogen, Cambridge, MA), and IL-la (Genzyme). Each treatment group represents the data obtained from 8 (16) . To more fully characterize this relationship with LPS, the activity of several adenine nucleotides was tested in a GTPase assay with macrophage membranes. Three distinct activities were observed ( Fig. 1 A-D GTPase activity may suggest that these adenine nucleotides do not activate RAW 264.7 macrophage purinoreceptors under basal conditions. Both analogs are poorly hydrolyzed or are nonhydrolyzable, yet both synergize with LPS to an extent similar to that of ATP and ADP. This observation argues against the possibility that the increase in GTPase activity is simply due to the regeneration of GTP by a phosphoryltransferase in the presence ofATP. Furthermore, the finding that the GTPase activity was selectively stimulated by ATP, ADP, ATP[y-S], and AMP-P[NHJP but not by AMP or adenosine (data not shown) suggests that this activity may be initiated through a member of the P2 class of purinoreceptors, which have a similar specificity for adenine nucleotide activation (17) (18) (19) . In fact, G protein-coupled purinoreceptors have been reported in various macrophage cell lines (17) (18) (19) .
In terms of GTPase activation, a biphasic response to the adenine nucleotides was observed regardless of the presence of LPS. This may be due, in part, to competition for GTP binding by high levels of adenine nucleotides. Furthermore, biphasic responses have been observed in the stimulation of other purinoreceptors (22) .
Based on the hypothesis that a P2 class of purinoreceptor is associated with this LPS-sensitive GTPase, we studied the effects of 2-MeS-ATP on this activity because 2-MeS-ATP has been reported (i) to bind very tightly to and (ii) to selectively activate certain members ofthe P2 purinoreceptor family (19) . However, rather than stimulating basal GTPase activity and synergistically enhancing the LPS-activated GTPase, 2-MeS-ATP only enhanced the basal GTPase (Fig. lE) . Given that 2-MeS-ATP increased basal GTPase activity but did not enhance the LPS-stimulated response, we hypothesized that 2-MeS-ATP might be a partial agonist with respect to the adenine nucleotide-dependent LPS-stimulable signaling pathway and therefore might be able to block the synergistic activity stimulated by other more active adenine nucleotides. We tested this possibility by adding 2-MeS-ATP to a membrane GTPase assay with LPS and ADP (Fig. 2) . In these assays, 2-MeS-ATP was found to block the adenine nucleotide-dependent LPS-stimulable GTPase activity, consistent with its antagonism of an LPS signaling pathway.
Preliminary studies showed that 2-MeS-ATP was able to decrease the amount of TNF-a cytotoxic activity in the culture supernatant after treatment with LPS (23) . The antagonistic activity of 2-MeS-ATP was also assessed in an in vivo model of endotoxemia. Because the lethal effects of endotoxin have been reported to be initiated by the release of TNF-a, IL-1, and IL-6 (1-5), we assessed the effects of 2-MeS-ATP on serum levels of these cytokines in mice (Fig.  3) . Administration of this nucleotide decreased the serum concentrations of TNF-a at 1 hr and of IL-1 at 4 hr ( Fig. 3 A  and B) . The response to 2-MeS-ATP appears to be immunomodulatory rather than immunosuppressive because this nucleotide did not block IL-6 release, also measured at 4 hr (Fig. 3C) .
We also assessed the ability of 2-MeS-ATP to protect mice from a lethal challenge of LPS. As shown in Table 1 , most of the control animals died; however, the lethal effects of endotoxin were prevented by doses of 130 pg or 1300 jig of 2-MeS-ATP per mouse. Because 2-MeS-ATP is not resistant to from phosphate hydrolysis, the possibility exists that this protective effect is mediated through an adenosine derivative. Adenosine and adenosine derivatives have been noted by others to affect cardiac contractility, smooth muscle tone in the vasculature, and immunologic responses to endotoxin (24, 25) . To test this possibility, the first two phosphohydrolyzed metabolites of2-MeS-ATP-namely, 2-MeS-ADP and 2-MeS-AMP-were administered. If 2-MeS-adenosine is the active species, then these compounds would also be predicted to protect mice from endotoxic death. However, when mice were challenged with a 100%o lethal dose (LDIoo) of LPS, 1 per mouse. These data imply a structural specificity for in vivo protection and argue against a metabolite being the active species. The enhanced survival by the intravenous administration of a nucleotide analog correlated with predictions based on the results in the GTPase assay and cell culture. Taken together, these data suggest that extracellular adenine nucleotides can influence the amount oftoxicity induced by LPS. That this effect is mediated through purinoreceptors is supported by the observations that purinoreceptors are normally expressed in macrophages (17) (18) (19) ; that ATP, ADP, and other purines are released from host cells during injury (17, 20) ; and that 2-MeS-ATP is effective within 1 hr in vivo (Fig. 3A) There also are several possibilities for the mechanism of action of 2-MeS-ATP which include: (i) 2-MeS-ATP and/or a metabolite may act as a competitive inhibitor against other adenine nucleotides such as ADP and ATP for binding to a purinoreceptor; (ii) 2-MeS-ATP and/or a metabolite may modulate a specific purinoreceptor or its downstream effects by binding to a separate class of purinoreceptor; and (iii) 2-MeS-ATP and/or a metabolite may directly affect a negative regulatory pathway for TNF-a and IL-1 release. Ultimately, the purification of the components in the LPSstimulated adenine nucleotide-regulated GTPase activity will be required to define the mechanism more clearly. Nevertheless, an alternative approach for the treatment of endotoxemia is provided by the fundamental observations that purinoreceptors appear to modulate endotoxin action in vitro and that an adenine nucleotide analog prevented endotoxic death in mice.
